BRIEF published on 11/14/2025 at 18:25, 9 months 26 days ago Relief Therapeutics Shareholders Approve Merger with NeuroX Leadership Changes Shareholder Approval Capital Increase Relief Therapeutics NeuroX Merger
BRIEF published on 11/14/2025 at 18:25, 9 months 26 days ago Les actionnaires de Relief Therapeutics approuvent la fusion avec NeuroX Augmentation De Capital Approbation Des Actionnaires Thérapeutiques De Soulagement Fusion De NeuroX Changements De Leadership
PRESS RELEASE published on 11/14/2025 at 18:20, 9 months 26 days ago Relief Therapeutics Shareholders Approve Business Combination with NeuroX Relief Therapeutics shareholders approve business combination with NeuroX, creating a digital neurotherapeutics company. New board members elected. Business combination expected to close in December 2025 Shareholders Business Combination Relief Therapeutics NeuroX Digital Neurotherapeutics
BRIEF published on 10/29/2025 at 07:05, 10 months 13 days ago Relief Therapeutics Reports Positive Outcomes in RLF-OD032 Study FDA Approval RLF-OD032 Phenylketonuria Treatment Bioequivalence Study Sapropterin Dihydrochloride
BRIEF published on 10/29/2025 at 07:05, 10 months 13 days ago Relief Therapeutics annonce des résultats positifs dans l'étude RLF-OD032 Approbation De La FDA RLF-OD032 Traitement De La Phénylcétonurie Étude De Bioéquivalence Dichlorhydrate De Saproptérine
PRESS RELEASE published on 10/29/2025 at 07:00, 10 months 13 days ago Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 Relief Therapeutics announces positive results from pivotal bioequivalence study of RLF-OD032, demonstrating bioequivalence to KUVAN®, supporting NDA submission in early 2026 FDA Approval Relief Therapeutics RLF-OD032 Bioequivalence Study PKU Treatment
BRIEF published on 10/24/2025 at 07:04, 10 months 18 days ago Relief Therapeutics Schedules Extraordinary General Meeting for Business Merger Business Combination Extraordinary General Meeting Relief Therapeutics MindMaze Therapeutics NeuroX Group
BRIEF published on 10/24/2025 at 07:04, 10 months 18 days ago Relief Therapeutics convoque une assemblée générale extraordinaire pour une fusion d'entreprises Assemblée Générale Extraordinaire THÉRAPEUTIQUE DE SECOURS Regroupement D'entreprises MindMaze Therapeutics Groupe NeuroX
PRESS RELEASE published on 10/24/2025 at 06:59, 10 months 18 days ago Relief Therapeutics Convenes Extraordinary General Meeting Relief Therapeutics announces Extraordinary General Meeting to seek shareholder approval for business combination with NeuroX Group SA EGM Business Combination Extraordinary General Meeting Relief Therapeutics NeuroX Group SA
BRIEF published on 10/08/2025 at 07:05, 11 months 3 days ago Relief Therapeutics and NeuroX Finalize Business Combination Agreement Mergers & Acquisitions NeuroX AI-driven Health Tech Precision Neurology MindMaze Therapeutics
Published on 09/11/2026 at 13:00, 14 minutes ago Silver Tiger Intersects 2.1 Metres of 7.72 Kilograms Per Tonne Silver Equivalent in the Caleigh Vein Including 0.53 Metres of 29.62 Kilograms
Published on 09/11/2026 at 04:00, 9 hours 14 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 49 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 54 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/11/2026 at 13:00, 14 minutes ago Gastech 2026: The Global Energy Industry Arrives in Bangkok as Asia Drives the Next Chapter of Energy Growth
Published on 09/11/2026 at 11:43, 1 hour 31 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 1 hour 38 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 1 hour 44 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 07:00, 6 hours 14 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 6 hours 14 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 6 hours 14 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 17 hours 44 minutes ago Availability of the 2026 Interim Financial Report
